Silvan Tuerkcan

Stock Analyst at Citizens

(4.48)
# 358
Out of 5,182 analysts
177
Total ratings
49.43%
Success rate
24.18%
Average return

Stocks Rated by Silvan Tuerkcan

Terns Pharmaceuticals
Mar 26, 2026
Downgrades: Market Perform
Price Target: n/a
Current: $52.95
Upside: -
CRISPR Therapeutics AG
Dec 23, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $50.99
Upside: +68.66%
Nuvation Bio
Nov 20, 2025
Maintains: Market Outperform
Price Target: $8$10
Current: $4.56
Upside: +119.30%
enGene Therapeutics
Nov 12, 2025
Maintains: Market Outperform
Price Target: $18$21
Current: $7.20
Upside: +191.67%
Intellia Therapeutics
Nov 7, 2025
Maintains: Market Outperform
Price Target: $29$21
Current: $13.04
Upside: +61.04%
Taysha Gene Therapies
Nov 5, 2025
Maintains: Market Outperform
Price Target: $6$8
Current: $6.46
Upside: +23.84%
Benitec Biopharma
Nov 4, 2025
Maintains: Market Outperform
Price Target: $20$22
Current: $12.61
Upside: +74.46%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12$6
Current: $0.93
Upside: +545.23%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30$34
Current: $9.62
Upside: +253.43%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41$45
Current: $29.48
Upside: +52.65%
Reiterates: Market Outperform
Price Target: $50
Current: $44.65
Upside: +11.98%
Reiterates: Market Outperform
Price Target: $15
Current: $7.50
Upside: +100.00%
Maintains: Market Outperform
Price Target: $10$6
Current: $3.67
Upside: +63.49%
Reiterates: Market Outperform
Price Target: $9
Current: $5.21
Upside: +72.74%
Downgrades: Market Perform
Price Target: $120
Current: $14.12
Upside: +749.86%
Reiterates: Market Outperform
Price Target: $17
Current: $1.88
Upside: +804.26%
Initiates: Market Outperform
Price Target: $4
Current: $2.34
Upside: +70.94%
Reiterates: Market Outperform
Price Target: $21
Current: $14.95
Upside: +40.47%
Downgrades: Market Perform
Price Target: n/a
Current: $3.05
Upside: -
Reiterates: Market Outperform
Price Target: $6
Current: $4.01
Upside: +49.63%
Maintains: Buy
Price Target: $240$280
Current: $68.02
Upside: +311.64%
Maintains: Market Outperform
Price Target: $18$18
Current: $11.02
Upside: +63.34%